For nearly a year, the nomination of Dr. Casey Means to serve as the next U.S. Surgeon General has been mired in controversy, drawing public rebuke not just from political opponents but from within the very administration that selected her. The standoff reached a new level in March 2026, when Jerome Adams—President Donald Trump’s first surgeon general—stepped forward to declare Means “fundamentally unqualified” for the nation’s top public health post. His intervention has added significant weight to a debate that already had the Senate at an impasse, with both parties expressing deep reservations about Means’ credentials and worldview.
Jerome Adams, who served as the country’s chief medical spokesperson during the COVID-19 pandemic, has repeatedly and vocally opposed Means’ nomination. According to The Washington Post, Adams’ central argument is simple: Means does not hold an active medical license and never completed a medical residency, meaning she has never practiced medicine as a licensed physician. “The surgeon general should be someone who has actually practiced medicine,” Adams stated, as reported by Audacy. His stance is not a mere partisan jab; Adams’ willingness to break with the president who appointed him underscores the gravity with which he views this issue. He has emphasized that the surgeon general’s role has “centuries of precedent and requirements, and she doesn’t meet them.”
Means’ path to nomination was unconventional from the start. A Stanford Medical School graduate, she began a surgical residency but dropped out during her final year, later explaining she left because she viewed the healthcare system as exploitative. She has since built a career as a wellness influencer and best-selling author, co-founding a healthcare technology company and amassing a large social media following with her advocacy for metabolic health, food safety, and environmental toxin awareness. Her book, “Good Energy,” has become a touchstone for the Make America Healthy Again (MAHA) movement, which is closely aligned with Health Secretary Robert F. Kennedy Jr. and skeptical of mainstream medical institutions.
President Trump nominated Means after withdrawing the nomination of Dr. Janette Nesheiwat, whose own confirmation faced significant hurdles. The White House’s pivot to Means was widely seen as a nod to the MAHA movement’s priorities—emphasizing chronic disease prevention and lifestyle interventions over traditional medicine. However, this shift came with substantial risks. Means’ alignment with vaccine skepticism, as well as her antagonism toward established medical authorities, became a lightning rod during her Senate confirmation hearing in February 2026.
At that hearing, Means declined to give direct answers on questions about childhood vaccine schedules, according to The Guardian. This evasiveness alarmed senators from both sides of the aisle. Two Republican senators, in particular, told Politico they remained undecided after the hearing—a critical detail in a narrowly divided Senate. As of late March 2026, Means’ nomination had been stalled for nearly 11 months, with no clear path to a floor vote. The nomination hearing record, documented as S.Hrg. 119-128 for the 119th Congress, details the proceedings and the bipartisan skepticism that has emerged.
Means’ critics, including Adams, argue that the surgeon general must possess not only scientific expertise but also the credibility to provide evidence-based public health information to the country. The role, often referred to as the “nation’s doctor,” requires someone who can command respect from both the medical community and the public. Adams has pointed out a particularly striking irony: if Means were confirmed, she would not be appointed as a physician in the Public Health Service Commissioned Corps—a 6,000-person force she would be expected to lead—but rather as a health-service worker, because she lacks a valid medical license.
Means has defended her qualifications by highlighting her leadership in health technology, her best-selling book, and her speaking engagements on chronic disease. She placed her Oregon medical license in inactive status, explaining that she was not seeing patients in recent years. When pressed about criticism from former surgeons general, Means deflected, writing, “Notably, under the tenures of our recent past Surgeon Generals, America’s health and lifespans have worsened.” However, this response sidestepped the core issue of her own lack of clinical experience and licensure.
According to NPR, Means’ supporters argue that her approach brings much-needed innovation to the office, focusing on food systems, chronic illness, and environmental health. The MAHA movement, which has championed her nomination, sees her as a fresh voice who can challenge the status quo. Yet, even among Trump’s base, some question whether a wellness influencer with no active medical license is the right choice for a position that has historically required deep clinical and administrative experience.
The consequences of a stalled or failed nomination go beyond political optics. The surgeon general’s office is responsible for issuing public health advisories, directing the Public Health Service Commissioned Corps, and shaping the federal government’s messaging on issues ranging from opioids to obesity to infectious disease. Without a Senate-confirmed leader, the office’s ability to respond decisively to public health threats is diminished. For the White House, the prospect of launching a third search for a surgeon general in a single term signals internal disarray at a time when the administration is pursuing sweeping changes to Medicaid and federal health agencies.
Three scenarios now loom over the Means nomination. The White House could intensify its lobbying, attempting to persuade the two undecided Republican senators to support Means and clear a path to a floor vote. Alternatively, Means could withdraw her nomination, as Nesheiwat did before her, prompting Trump to select a third candidate. The most likely outcome, at least for now, is continued limbo—with the nomination neither confirmed nor withdrawn and the office operating without a permanent leader.
Adams’ continued public opposition makes it increasingly difficult for the White House to rally support. His stature as a former surgeon general and his own experience leading the nation through a public health crisis lend his criticism credibility that cannot be easily dismissed as partisan or personal. The broader pattern is also telling: the MAHA movement’s influence on health nominations has resulted in one withdrawal and a second stalled confirmation, while Senate Republicans have demonstrated a willingness to block nominees whose views and credentials fall outside mainstream medical standards—even when those nominees have White House and activist backing.
All eyes are now on the two wavering Republican senators. Their public statements in the coming weeks will reveal whether the White House has the votes to move forward or if another search is inevitable. For a role that shapes how the federal government communicates with Americans about their health, the outcome will have real and lasting consequences—not just for the Trump administration, but for the country’s public health leadership at large.